For both CLL cell lines, the magnitude of extracellular HMGB1 released appeared to be greatest from lower concentrations of SpiD3 (0.25–0.5 μM) in a prolonged treatment setting (beyond 24 h; Figure 3). The gene discussed is HMGB1; the disease is B-cell chronic lymphocytic leukemia.